Recommendations for research

The guideline committee has made the following key recommendations for research.

1 Surgery to the breast

What is the optimum tumour‑free margin width after breast‑conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer?

For a short explanation of why the committee made the recommendation for research, see the rationale section on surgery to the breast.

Full details of the evidence and the committee's discussion are in evidence review A: surgery to the breast.

2 Adjuvant bisphosphonate therapy

Which groups of people with early and locally advanced breast cancer would benefit from the use of adjuvant bisphosphonates?

For a short explanation of why the committee made the recommendation for research, see the rationale section on adjuvant bisphosphonate therapy.

Full details of the evidence and the committee's discussion are in evidence review G: adjuvant bisphosphonates.

3 Breast reconstruction

What are the long‑term outcomes for breast reconstruction in women having radiotherapy to the chest wall?

For a short explanation of why the committee made the recommendation for research, see the rationale section on breast reconstruction.

Full details of the evidence and the committee's discussion are in evidence review I: postmastectomy radiotherapy.

4 Neoadjuvant endocrine therapy in premenopausal women

Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer?

For a short explanation of why the committee made the recommendation for research, see the rationale section on neoadjuvant endocrine therapy.

Full details of the evidence and the committee's discussion are in evidence review J: neoadjuvant treatment of early and locally advanced breast cancer.

5 Neoadjuvant endocrine therapy in postmenopausal women

Is there a benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer?

For a short explanation of why the committee made the recommendation for research, see the rationale section on neoadjuvant endocrine therapy.

Full details of the evidence and the committee's discussion are in evidence review J: neoadjuvant treatment of early and locally advanced breast cancer.

6 Neoadjuvant treatment

What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

For a short explanation of why the committee made the recommendation for research, see the rationale section on radiotherapy after neoadjuvant chemotherapy.

Full details of the evidence and the committee's discussion are in evidence review J: neoadjuvant treatment of early and locally advanced breast cancer.

  • National Institute for Health and Care Excellence (NICE)